Lv2
138 积分 2026-05-22 加入
Treatable traits in interstitial lung disease: opportunities and challenges
14小时前
已完结
1197P Limited clinical benefit of chemotherapy in ovarian cancer patients progressing during or after PARPi maintenance treatment
1个月前
已关闭
Exploiting the folate receptor α in oncology
2个月前
已完结
Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
2个月前
已关闭
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
2个月前
已关闭
Duplexed CeTEAM drug biosensors reveal determinants of PARP inhibitor selectivity in cells
2个月前
已完结
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
2个月前
已完结
New payloads drive next-gen antibody–drug conjugates
3个月前
已完结
Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure
3个月前
已完结
Two decades of PARP inhibitor synthetic lethality in cancer
3个月前
已完结
皖公网安备34019202002308
